Randomized Phase IB/II Study of Enzalutamide With and Without Ribociclib in Patients With Metastatic Castrate Resistant, Chemotherapy Naïve Prostate Cancer That Retains RB Expression

Trial Profile

Randomized Phase IB/II Study of Enzalutamide With and Without Ribociclib in Patients With Metastatic Castrate Resistant, Chemotherapy Naïve Prostate Cancer That Retains RB Expression

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Feb 2018

At a glance

  • Drugs Ribociclib (Primary) ; Enzalutamide
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 16 Feb 2018 According to trial design presented at the 2018 Genitourinary Cancers Symposium, dose levels 1 and 2 have been completed without any DLTs in the phase I portion and a review was planned for dose level 3 in Oct 2017.
    • 16 Feb 2018 Trial design presented at the 2018 Genitourinary Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top